Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder

The study will evaluate the efficacy, safety, and tolerability of 225 milligrams (mg) and 450 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).

Study Overview

Status

Terminated

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Gyongyos, Hungary, 3200
        • Bugát Pál Hospital, Clinexpert
      • Ichigayatamachi, Japan, 162-0843
        • Himorogi Psychiatric Institute
      • Kawasaki-shi, Japan, 214-0014
        • Kishiro Mental Clinic
      • Kobe-shi, Japan, 651-0097
        • Tatsuta Clinic
      • Kumamoto-shi, Japan, 861-8002
        • Medical corporation Sato-Kai Yuge Hospital
      • Kyoto-shi, Japan, 616-8421
        • Sagaarashiyama-Tanaka Clinic
      • Meguro-ku, Japan, 152-0012
        • Senzoku Psychosomatic Medicine Clinic
      • Sapporo-shi, Japan, 003-0003
        • Higashi Sapporo Mental Clinic
      • Setagaya-ku, Japan, 154-0004
        • Sangenjaya Neurology- Psychosomatic Clinic
      • Shibuya-ku, Japan, 151-0051
        • Yoyogi Mental Clinic
      • Shibuya-ku, Japan, 151-0053
        • Maynds Tower Mental Clinic
      • Shinagawa-ku, Japan, 141-0032
        • Himeno Tomomi Clinic
      • Shinjuku-ku, Japan, 169-0073
        • Shinjuku Research Park Clinic
      • Toshima-ku, Japan, 170-0002
        • Ohwa Mental Clinic
      • Toyoake-city, Japan, 470-1168
        • Okehazama Hospital Fujita Kokoro Care Center
      • Yokohama-shi, Japan, 231-0015
        • Yokohama Onoecho Clinic
      • Lublin, Poland, 20-109
        • Centrum Medyczne Luxmed Sp.z o.o.
      • Moscow, Russian Federation, 115522
        • Federal State Budgetary Research Institution "Mental Health Science Center"
      • Yaroslavl, Russian Federation, 150003
        • Yaroslavl Regional Psychiatric Hospital
      • Bratislava, Slovakia, 82007
        • MENTUM, s.r.o.
      • Bratislava, Slovakia, 85101
        • Vavrusova Consulting s.r.o. Neštátna Psychiatrická ambulancia
      • Liptovsky Mikulas, Slovakia, 03123
        • Liptovská nemocnica s poliklinikou MUDr. Ivana Stodolu Liptovský Mikuláš
      • Rimavska Sobota, Slovakia, 97901
        • PsychoLine s.r.o.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 73 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for MDD
  • Current major depressive episode of at least 8 weeks and not exceeding 18 months in duration at Visit 1
  • Treatment naive in the current episode or have inadequate response to 1-3 antidepressant therapies given at adequate dose and duration in the current episode
  • If female of childbearing potential, have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test

Exclusion Criteria:

  • DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of treatment within 6 months before Visit 1
  • Lifetime history of meeting DSM-5 criteria for:

    1. Schizophrenia spectrum or other psychotic disorder
    2. Bipolar or related disorder
    3. Major neurocognitive disorder
    4. Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study
    5. Dissociative disorder
    6. Posttraumatic stress disorder
    7. MDD with psychotic features
  • Significant suicide risk, as judged by the investigator

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Rapastinel 450mg
Rapastinel (prefilled syringe, weekly intravenous IV administration).
Rapastinel (prefilled syringe, weekly intravenous IV administration).
Experimental: Rapastinel 225mg
Rapastinel (prefilled syringe, weekly intravenous IV administration).
Rapastinel (prefilled syringe, weekly intravenous IV administration).
Placebo Comparator: Placebo
Placebo (prefilled syringe, weekly IV administration).
Placebo (prefilled syringe, weekly IV administration).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at End of Double-blind Treatment (End of Week 6).
Time Frame: Baseline to end of Week 6
The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.
Baseline to end of Week 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in MADRS Total Score at 1 Day After First Dose of Treatment
Time Frame: Baseline to 1 Day post-first dose
The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.
Baseline to 1 Day post-first dose

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 30, 2018

Primary Completion (Actual)

July 11, 2019

Study Completion (Actual)

July 11, 2019

Study Registration Dates

First Submitted

September 17, 2018

First Submitted That Met QC Criteria

September 17, 2018

First Posted (Actual)

September 18, 2018

Study Record Updates

Last Update Posted (Actual)

July 28, 2020

Last Update Submitted That Met QC Criteria

July 10, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • RAP-MD-30
  • 2018-000060-29 (EudraCT Number)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depressive Disorder, Major

Clinical Trials on Rapastinel

3
Subscribe